Active ingredient description

Abrocitinib is a Janus kinase (JAK)1 inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of haematopoiesis and immune cell function. It is used for the treatment of moderate-to-severe atopic dermatitis in adults.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
D Dermatologicals → D11 Other dermatological preparations → D11A Other dermatological preparations → D11AH Agents for dermatitis, excluding corticosteroids
Discover more medicines within D11AH08

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Summary of Product Characteristics (SPC)

Structural formula

Graphic representation of the active ingredient's molecular structure

Chemical formula: C₁₄H₂₁N₅O₂S
Molecular mass: 323.42 g/mol

External identifiers

CAS Substance: 1622902-68-4
DrugBank Drug: DB14973
PubChem Compound: 78323835
RxNorm Ingredient: 2591476
UNII Identifier: 73SM5SF3OR


Abrocitinib is an active ingredient of these brands:

Estonia (EE)

Finland (FI)

Ireland (IE)

Japan (JP)

Poland (PL)

Romania (RO)

Turkey (TR)

United Kingdom (UK)

While we strive to include the brand names of medicines across all countries, our index remains incomplete. Therefore, it is possible that this medicine may also be marketed under different names in other countries.